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An increased fracture risk has been described as a complication of Type 2 diabetes mellitus
(T2DM). Clinical prediction models for general population have a limited predictive accuracy
for fractures in T2DM patients. The aim was to develop and validate a clinical prediction tool
for the estimation of 5-year hip and major fracture risk in T2DM patients.
Methods and results
A cohort of newly diagnosed T2DM patients (n = 51,143, aged 50–85, 57%men) was
extracted from the Information System for the Development of Research in Primary Care
(SIDIAP) database, containing computerized primary care records for >80% of the popula-
tion of Catalonia, Spain (>6 million people). Patients were followed up from T2DM diagnosis
until the earliest of death, transfer out, fracture, or end of study. Cox proportional hazards
regression was used to model the 5-year risk of hip and major fracture. Calibration and dis-
crimination were assessed. Hip and major fracture incidence rates were 1.84 [95%CI 1.64
to 2.05] and 7.12 [95%CI 6.72 to 7.53] per 1,000 person-years, respectively. Both hip and
major fracture prediction models included age, sex, previous major fracture, statins use, and
calcium/vitamin D supplements; previous ischemic heart disease was also included for hip
fracture and stroke for major fracture. Discrimination (0.81 for hip and 0.72 for major frac-
ture) and calibration plots support excellent internal validity.
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Conclusions
The proposed prediction models have good discrimination and calibration for the estimation
of both hip and major fracture risk in incident T2DM patients. These tools incorporate key
T2DMmacrovascular complications generally available in primary care electronic medical
records, as well as more generic fracture risk predictors. Future work will focus on validation
of these models in external cohorts.
Introduction
Type 2 diabetes mellitus (T2DM) is one of the most prevalent long-term comorbidities in the
western world, especially in elderly and obese patients. Affecting at least 285 million people
worldwide, the number of cases is expected to reach 438 million by the year 2030[1].
An increased fracture risk has been described as a complication of T2DM[2]. Screening or
targeting T2DM patients at high fracture risk is a challenge. Bone mineral density (BMD) as
measured by dual energy X-ray absorptiometry (DXA) is not sensitive enough[3], and predic-
tion models like FRAX have a limited predictive accuracy for fractures in T2DM patients[4–7].
A few studies have found non-differentiated[8,9] or lower BMD[10] in patients with T2DM,
compared to the general population, but the vast majority of studies show a higher/elevated
BMD in T2DM as shown by two meta-analyses [11,12].
Disease history (e.g., time from onset, metabolic control) appears to contribute to this asso-
ciation with fracture, as the risk seems to be increased only in individuals with T2DM, whether
newly diagnosed[13] or established [14,15], while an impairment in glucose tolerance or fast-
ing glucose is associated with fracture risk lower than or comparable to nondiabetic individu-
als[15]. Other factors, both skeletal and extra-skeletal, could play a role in the excess risk of
fracture observed in T2DM patients. Indeed, T2DM complications such as neuropathy,
nephropathy, and visual impairment due to diabetic retinopathy or cataracts are associated
with an increased number of falls and related fractures[16–18]. Moreover, changes in bone tis-
sue composition may contribute to a deterioration of bone biomechanical properties[19].
In addition, antidiabetic drugs such as thiazolidinediones have a harmful effect on BMD
and fracture risk[20–22] and some studies have associated insulin use with an increased risk of
fracture [23,24]. The effect on bone metabolism of some other drugs remains unclear; this
includes metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like
peptide 1 (GLP-1) agonists, and sodium-glucose transport protein2 (SGLT2) inhibitors [25–
31]. Moreover, two recent systematic reviews and meta-analysis of epidemiologic studies on
the association between T2DM and fracture risk found a significant positive association
between T2DM and hip, vertebral, or foot fractures[32,33].
The specific aim of the present study was to develop a clinical prediction model for the esti-
mation of absolute risk of hip and major fracture in T2DM patients. Secondly, we studied the
calibration and discrimination performance of the prediction model obtained.
Materials andmethods
Data source/s
The protocol of the study was approved at the first site by the Research Ethics Committee
(REC) of IDIAP Jordi Gol. Data were extracted from the Information System for the Develop-
ment of Research in Primary Care (Catalan acronym, SIDIAP: www.sidiap.org). The SIDIAP
database provides anonymized clinical information as coded by general practitioners in 274
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primary care practices in Catalonia, Spain, covering more than 6 million patients (80% of the
Catalan population). The representativeness of the SIDIAP database for the overall Catalan
population has been reported elsewhere[34].
SIDIAP contains information on socio-demographics, primary care visits, referrals, diag-
nostic codes using the 10th edition of the International Classification of Diseases (ICD-10),
clinical data and immunizations, and other clinical information. SIDIAP is linked to pharmacy
invoice data, which provides detailed information on drugs dispensed in community pharma-
cies under the universal health care system.
SIDIAP data has been previously used to study other aspects related to T2DM assessment
and treatment[34] as well as to characterize the epidemiology and describe new predictors of
fragility fractures[35–38].
Participants
Our study cohort consisted of all newly diagnosed T2DM patients aged between 50 and 85
years, identified in SIDIAP database records with a T2DM diagnostic date between 1 January
2006 and 31 December 2013. Patients with any recorded comorbidity that is commonly con-
sidered as secondary osteoporosis and those with advanced chronic renal disease (glomerular
filtration<15) were not considered and their data were not extracted from the SIDIAP data-
base. The comorbidity exclusion criteria were type I diabetes, osteogenesis imperfecta, hyper-
thyroidism, hypogonadism or premature menopause, chronic malnutrition or malabsorption,
and chronic liver disease. Included participants were followed up from the time of T2DM diag-
nosis until the earliest of transfer out/migration, fracture, death, or end of study (31 December
2013).
Eligible patients treated before the date of T2DM diagnosis with any anti-osteoporosis drug
(bisphosphonates, strontium, calcitonin, selective estrogen receptor modulator, and hormone
replacement therapy) were excluded. Fig 1 contains a flow chart of the inclusion process.
Study outcomes
Main outcomes were incident hip fracture and incident major fracture (hip, clinical spine,
wrist/forearm, and proximal humerus), identified by previously validated ICD-10 codes[39].
Potential predictors
The initial set of 35 candidate risk factors to be included in the model was pre-specified based
on the literature (i.e., variables potentially associated with increased risk of falls, low BMD, or
fragility fractures). These included the following:
1. socio-demographics: age, sex
2. lifestyle factors: body mass index (BMI), alcohol, smoking status
3. laboratory measurements: glycated haemoglobin (HbA1c), and renal function (estimated
glomerular filtration rate based on the MDRD4 formula).
4. medications: use of oral corticosteroids for 3 months or more (>5 mg of prednisolone or
equivalent), thiazide diuretics, angiotensin-converting enzyme inhibitors, statins, and cal-
cium and vitamin D supplements.
5. co-morbidities: previous record of ischemic heart disease (including angina and myocardial
infarction), cerebrovascular disease (CVD), transient ischemic attack, nephropathy, neu-
ropathy, osteoarthritis, cataracts, major fractures, hypoglycemia, and falls.
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Interactions were assessed between age and previous major fractures, ischemic disease,
nephropathy, and osteoarthritis, and between sex and previous major fractures and oral corti-
coids. All continuous predictors were assumed to have a linear association with the outcome.
Medications were identified using a pre-specified list of World Health Organization Ana-
tomic Therapeutic Classification (WHO ATC) codes. Co-morbidities were identified using
ICD-10 codes. For BMI, HbA1c, estimated glomerular filtration rate (renal function), and
smoking status, only results coded within 5 years before the index date were used, selecting the
measurement closest to the index date if multiple values were available.
Statistical analyses
Baseline characteristics of T2DM patients were described using mean and standard deviation
for continuous variables and frequencies for categorical variables. Cox regression was used to
Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0203533.g001
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derive two predictive models for the 5 years following T2DM diagnosis, based on the patient’s
medical history and clinical findings: (1) hip fracture risk and (2) major fracture risk.
To develop and validate the clinical prediction model, we followed 7 steps: descriptive anal-
ysis, multiple imputations of missing data, bootstrapping, backwards selection of predictors,
derivation of a final model, model estimation on imputed data, and models assessment.
First, a descriptive analysis of the assessed factors against outcome was done. Multiple
imputation with chained equations (MICE) was then used to minimize the impact of missing
data for BMI, HbA1c, serum creatinine (used to calculate renal function), and smoking status.
Ten datasets were created, using the Gaussian normal regression method to impute continu-
ous variables (BMI, HbA1c, creatinine) and the multinomial logistic regression method to
impute smoking status. Each imputed dataset was sampled by bootstrapping with replacement
100 times, totaling 1,000 samples. Models were fitted for each of the 1,000 samples using back-
wards elimination (significance level for removal from the model was 0.157). Predictors
retained in more than 80% of the 1,000 estimated models were considered for inclusion in the
final model. A model with the selected predictors was then estimated using the 10 imputed
samples and adjusting coefficients and standard errors for the variability between imputations
according to the Rubin rules[40,41]. Finally, discrimination was assessed by estimating Har-
rell’s C statistics for the final models derived. To assess calibration, observed versus expected
fractures were compared graphically by tenths of predicted risk, by 5-year age groups, and by
sex. A bootstrapping method[42] was used for internal validation of the estimated models. All
data were analyzed using STATA software (StataCorp. 2013. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP) and the Regression Modeling Strategies (rms) package
(Frank E Harrell Jr. 2017. R package version 5.1–0.) of R software (R Core Team. 2017. R: A
language and environment for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria).
Results
The flow chart of participant inclusion is shown in Fig 1, above. Baseline characteristics of the
study participants were stratified by outcome status (Table 1). Patients who sustained a frac-
ture during follow-up were more frequently older, women, systemic steroid users, and had a
higher number of associated comorbidities and prevalence of previous fracture/s.
We identified 51,143 newly diagnosed cases of T2DM, observed for a total follow-up of
170,795.3 patient-years for hip fracture, with a median 3.3-year follow-up (interquartile range
from 1.7 to 4.9 years). Follow-up for major fracture analysis totaled 168,795.2 patient-years,
with a median 3.2-year follow-up (interquartile range from 1.6 to 4.9 years). During follow-up,
a total of 314 patients suffered a hip fracture; incidence rate was 1.84 [95%CI 1.64 to 2.05] per
1,000 persons per year. Major fracture occurred in 1,201 patients, an incidence rate of 7.12
[95%CI 6.72 to 7.53] per 1,000 persons per year. Key predictors of hip and major fracture and
the proportion of bootstrap models in which they were retained are reported in the S1 Table;
HRs for estimated hip and major fracture models are shown in Figs 2 and 3, respectively.
In our cohort, no patient had a combination of factors that predicted a 5-year risk of hip or
major fracture greater than>8% or 18%, respectively. Therefore, our data do not allow for
accurate prediction above these thresholds, and any extrapolations are of limited reliability.
This model could be useful to clinicians as well as researchers to estimate an individual’s pro-
file for 5-year risk of developing a hip or major fracture. The web-based calculator would
make it easy for physicians to apply our predictive model. The prediction could then be used
to identify subjects at high or low risk of fracture so they can be assessed to manage and reduce
their risk. Equations and illustrative examples for the calculation of hip and major fracture risk
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are reported in supplemental files (S1 and S2 Files, respectively) and the online version of both
tools is available at https://research.ndorms.ox.ac.uk/fred/. Nonetheless, prediction tools like
the ones presented here cannot be used for clinical management until approval has been
obtained from regulatory authorities.
The derived clinical prediction model for hip fracture risk had excellent discrimination,
with Harrell´s C statistics of 0.81. Calibration showed a good observed/expected ratio for all
strata of predicted risk and age/sex combinations (Figs 4 and 5). The proposed model for
major fracture prediction also had good discrimination, with Harrell´s C statistic of 0.72, and
excellent calibration for all the observed strata (Figs 4 and 5). Internal validation using boot-
strap resampling yielded satisfactory results for both models. Corrected Harrell’s C index was
0.81 for the hip model and 0.72 for the major fracture model. Calibration plots illustrated con-
sistent accuracy from the original model and the bootstrap model; the absolute error for 5-year
prediction was close to 0.
Discussion
We describe two prediction models for the estimation of hip and major fracture risk in inci-
dent T2DM patients. These models were based on primary care data that are readily available










Mean (SD) age (years) 64.86 (9.28) 74.89 (8.39) 64.79 (9.27) 70.16 (9.63)
Mean (SD) body mass index (Kg/m2) 31.11 (5.06) 29.97 (5.10) 31.11 (5.06) 30.89 (5.26)
Missing body mass index 20,554 (40.44) 127 (40.32) 20,271 (40.59) 410 (34.14)
Sex (male) 29253 (57.55%) 105 (33.44%) 28990 (58.05%) 368 (30.64%)
Mean (SD) HbA1c 6.27 (1.32) 6.33 (1.35) 6.27 (1.32) 6.30 (1.38)
Missing HbA1c 29458 (57.96%) 169 (53.82%) 29076 (58.22%) 542 (45.13%)
Smoking status
Never 9037 (17.78%) 68 (21.66%) 8812 (17.64%) 293 (24.4%)
Current smoker 5795 (11.4%) 15 (4.78%) 5741 (11.5%) 69 (5.75%)
Ex-smoker 4787 (9.42%) 16 (5.1%) 4729 (9.47%) 74 (6.16%)
Missing data 31210 (61.4%) 215 (68.47%) 30660 (61.39%) 765 (63.7%)
Cerebrovascular disease 2846 (5.6%) 37 (11.78%) 2777 (5.56%) 106 (8.83%)
Ischemic heart disease 4770 (9.38%) 50 (15.92%) 4693 (9.4%) 127 (10.57%)
Chronic kidney disease 5076 (9.99%) 71 (22.61%) 4959 (9.93%) 188 (15.65%)
Neuropathy 330 (0.65%) 2 (0.64%) 321 (0.64%) 11 (0.92%)
Cataracts 4045 (7.96%) 45 (14.33%) 3952 (7.91%) 138 (11.49%)
History of falling 611 (1.2%) 10 (3.18%) 588 (1.18%) 33 (2.75%)
Osteoarthritis 11250 (22.13%) 103 (32.8%) 10985 (22%) 368 (30.64%)
Hypoglycemia 67 (0.13%) 0 (0%) 65 (0.13%) 2 (0.17%)
Previous hip fracture 200 (0.39%) 23 (7.32%) 190 (0.38%) 33 (2.75%)
Previous major fracture 893 (1.76%) 15 (4.78%) 808 (1.62%) 100 (8.33%)
Current medications
Oral steroids for3 months
3716 (7.31%) 37 (11.78%) 3634 (7.28%) 119 (9.91%)
Statins 23697 (46.62%) 135 (42.99%) 23293 (46.64%) 539 (44.88%)
Thiazides 6843 (13.46%) 45 (14.33%) 6706 (13.43%) 182 (15.15%)
Angiotensin enzyme inhibitors 18523 (36.44%) 128 (40.76%) 18193 (36.43%) 458 (38.13%)
Calcium and vitamin D 2729 (5.37%) 32 (10.19%) 2634 (5.27%) 127 (10.57%)
https://doi.org/10.1371/journal.pone.0203533.t001
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in electronic medical records: age, sex, previous major fracture, diabetic macrovascular com-
plications, use of statins, and previous prescription of calcium and vitamin D supplements. By
accounting for T2DMmacrovascular complications, these models identified T2DM patients at
high risk of fracture more accurately than previous tools derived for the general population
that included risk factors for osteoporosis/low bone density.
Age and sex are classic risk factors for osteoporotic fractures, and previous history of frac-
ture confers an increased risk of future fracture/s[43,44]. Our finding of a consistent inverse
association with statin use was more surprising, although a 23% reduction in fracture risk
amongst users of these drugs was previously reported [45].
In addition, a number of diabetic complications and comorbidities typically clustered in
T2DM patients appeared to be predictors of fracture in our models. The association between
T2DM and cardiovascular disease is well known[46–48], and increases with time from T2DM
onset as well as with poor metabolic control[49]. Previous studies have shown similar associa-
tions between fracture and cardiovascular disease, which is included as a predictor in the
model used by the QFracture score [50].
The role of vitamin D plus calcium as a risk factor in our major fracture model could be
disconcerting. Vitamin D and calcium supplementation is highly associated with a significant
Fig 2. Hazard Ratio and 95% confidence intervals for hip fracture predictors.HR: Hazard Ratio; IHD: Ischemic heart disease.
https://doi.org/10.1371/journal.pone.0203533.g002
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reduction in the incidence of non-vertebral fractures[51] and therefore has been used to pre-
vent osteoporotic fractures in patients with evidence or risk of vitamin D and/or calcium insuf-
ficiency[52]. Thus, the role of vitamin D and calcium in our model could be a proxy of the
severity of risk perceived by the prescriber, as people at higher risk of fracture are more likely
to receive these supplements.
Some antidiabetic drugs such as insulin appear to be associated with an increased fracture
risk. In our data, this association was not strong enough to include antidiabetic drugs in the
final model. In a cohort of prevalent, rather than incident, T2DM patients, antidiabetic drugs
likely would have shown a stronger association with fracture risk, as these patients are more
likely to be exposed to such medications. Insulin is associated with an increased fracture risk
in a number of studies[23,24] but not all[18,53]. On the other hand, non-insulin-dependent
patients have increased BMD and lower fracture risk, compared to users of insulin [54].
Increased fracture risk in T2DM patients has been associated, at least in part, with alter-
ations in bone remodeling and bone cell function[55]. Biochemical markers of bone formation
such as osteocalcin and telopeptide carboxy-terminal are decreased in T2DM patients[12].
Moreover, sclerostin, a negative regulator of bone formation which competes with the anabolic
Fig 3. Hazard Ratio and 95% confidence intervals for major fracture predictors.HR: Hazard Ratio; Ca + Vit D: Calcium/vitamin D supplements.
https://doi.org/10.1371/journal.pone.0203533.g003
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Wnt β-catenin pathway, is increased in T2DM patients [56] and associated with a higher risk
of vertebral fractures[57]. Higher sclerostin levels could reflect the presence of more deeply
embedded osteocytes in older bone that has accumulated more microscopic damage. Circulat-
ing sclerostin is also increased in T2DM patients with atherosclerotic lesions[58], suggesting a
connection with macrovascular complications of diabetes. Finally, bone quality could be con-
ditioned by an increase in advanced glycation endproducts in bone collagen due to a long
exposure to hyperglycemia, which would decrease bone resorption and contribute to fragility
fractures[59].
Fig 4. Observed vs predicted risk of hip (top) and major fracture (bottom), stratified by tenths of predicted risk.
https://doi.org/10.1371/journal.pone.0203533.g004
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Strengths and limitations
The main limitation of our data is the lack of validation of each individual fracture. However,
coding of fractures in SIDIAP has been compared to classical cohort data and hospital data-
bases and shown to be highly specific (>95% for all fracture sites tested) and moderately sensi-
tive (almost 70% for hip fractures)[39]. Also, ICD-10 does not distinguish between traumatic
fractures and fragility fractures. A recent study including a random sample of 300 SIDIAP par-
ticipants aged>50 years with a recorded fracture during 2012 found>90% of hip fractures
and>80% of major fractures due to fragility (not related to high-impact trauma)[60].
Another general limitation of our study is the timepoints when lifestyle factors were mea-
sured. To minimize misclassification, we only considered information on lifestyle factors as
recorded no more than five years before the index date. Smoking status[61], as well as heavy
alcohol intake[62], are well-known lifestyle risk factors for fracture. However, these factors
were not included in our model because alcohol intake and use of cigarettes are not accurately
Fig 5. Observed vs predicted risk of hip (top) and major fracture (bottom), stratified by age groups.
https://doi.org/10.1371/journal.pone.0203533.g005
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collected in the SIDIAP database[34], which generates a high number of missing values and a
reporting bias.
Important strengths of our data are the high number of patients studied and the robust sta-
tistical methods used, including multiple imputation to account for missing data and boot-
strapping to minimize overfitting. However, validation in a dataset different from the
development sample is required and is anticipated in the near future.
Conclusions
The proposed prediction models have good discrimination and calibration to estimate the
5-year risk of hip and major fracture in incident T2DM patients. These tools incorporate key
T2DMmacrovascular complications predictors generally available in primary care electronic
medical records, as well as more generic fracture risk predictors. Future work will focus on the
validation of our models in external cohorts.
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Formal analysis: Cristian Tebé, Daniel Prieto-Alhambra.
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